Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study to Assess Efficacy, Safety, Tolerability and Optimal Dose Ranging of XC8 in Doses 20, 100 and 200 mg Once Daily in Patients With Uncomplicated Influenza or Other Acute Respiratory Viral Infections (ARVI)

NCT03441373 is registered in ClinicalTrials.gov with PHARMENTERPRISES LLC as lead sponsor.

NCT NCT03441373
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03441373 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study to Assess Efficacy, Safety, Tolerability and Optimal Dose Ranging of XC8 in Doses 20, 100 and 200 mg Once Daily in Patients With Uncomplicated Influenza or Other Acute Respiratory Viral Infections (ARVI)
Lead sponsor
PHARMENTERPRISES LLC
Phase
Phase 2/3
Overall status
Completed
Start date
February 3, 2016
Completion date
February 9, 2017
Enrollment
320 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

acute respiratory infection, influenza